Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3
Open Access
- 6 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 4 (6), e655
- https://doi.org/10.1038/cddis.2013.192
Abstract
Past studies have shown that histone deacetylase (HDAC) and mutant BRAF (v-Raf murine sarcoma viral oncogene homolog B1) inhibitors synergistically kill melanoma cells with activating mutations in BRAF. However, the mechanism(s) involved remains less understood. Here, we report that combinations of HDAC and BRAF inhibitors kill BRAFV600E melanoma cells by induction of necrosis. Cotreatment with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) or panobinostat (LBH589) and the BRAF inhibitor PLX4720 activated the caspase cascade, but caspases appeared dispensable for killing, in that inhibition of caspases did not invariably block induction of cell death. The majority of dying cells acquired propidium iodide positivity instantly when they became positive for Annexin V, suggesting induction of necrosis. This was supported by caspase-independent release of high-mobility group protein B1, and further consolidated by rupture of the plasma membrane and loss of nuclear and cytoplasmic contents, as manifested by transmission electron microscopic analysis. Of note, neither the necrosis inhibitor necrostatin-1 nor the small interference RNA (siRNA) knockdown of receptor-interacting protein kinase 3 (RIPK3) inhibited cell death, suggesting that RIPK1 and RIPK3 do not contribute to induction of necrosis by combinations of HDAC and BRAF inhibitors in BRAFV600E melanoma cells. Significantly, SAHA and the clinically available BRAF inhibitor vemurafenib cooperatively inhibited BRAFV600E melanoma xenograft growth in a mouse model even when caspase-3 was inhibited. Taken together, these results indicate that cotreatment with HDAC and BRAF inhibitors can bypass canonical cell death pathways to kill melanoma cells, which may be of therapeutic advantage in the treatment of melanoma.Keywords
This publication has 63 references indexed in Scilit:
- TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1Cell Death & Disease, 2013
- Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease modelsCell Death & Disease, 2012
- Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 KinaseCell, 2012
- The Mitochondrial Phosphatase PGAM5 Functions at the Convergence Point of Multiple Necrotic Death PathwaysCell, 2012
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsInvestigational New Drugs, 2010
- Necroptosis as an alternative form of programmed cell deathCurrent Opinion in Cell Biology, 2010
- Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotesCell Death & Differentiation, 2009
- Identification of a Molecular Signaling Network that Regulates a Cellular Necrotic Cell Death PathwayCell, 2008
- Combined treatment with Ad‐hTRAIL and DTIC or SAHA is associated with increased mitochondrial‐mediated apoptosis in human melanoma cell linesThe Journal of Gene Medicine, 2007